Johnson & Johnson
↗New Brunswick, New Jersey, USA
Johnson & Johnson (J&J) is a multinational pharmaceutical, biotechnology, and medical devices corporation headquartered in New Brunswick, New Jersey, and publicly traded on the NYSE. Following the 2023 spin-off of its consumer health business, J&J now operates as a biopharmaceutical and medical devices company through two primary segments: Innovative Medicine and MedTech. The company's strength lies in building a world where complex diseases are prevented, treated, and cured, with treatments that are smarter, less invasive, and personalized. J&J maintains the world's strongest pharmaceutical brand value at USD 13.4 billion and is ranked as the most future-ready pharmaceutical company according to S&P Global and IMD metrics.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals|Biotechnology|Medical Devices
Sub-Industry:Innovative Medicine (Pharma & Biotech) | MedTech
SIZE & FINANCIALS
Employees:10000+
Revenue:$57.07B - $88.82B (2024 total revenue)
Founded:1886
Ownership:public
Status:operating
FUNDING
Stage:N/A
STOCK
Exchange:NYSE
Ticker:JNJ
Market Cap:$500.07B
PIPELINE
Stage:Discovery|Preclinical|Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 and Commercial - Talvey, Tecvayli, Carvykti, Imaavy approved; Icotrokinra in Phase 3 submissions
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-Drug Conjugates (ADC), CAR-T cell therapy, Bispecific antibodies, Gene therapy, Vaccines
Active Trials:500
Trial Phases:Phase 1: 150 | Phase 2: 200 | Phase 3: 100 | Phase 4: 50
FDA Approvals:50
EMA Approvals:40
CORPORATE STRUCTURE
Subsidiaries:Janssen Pharmaceuticals, Janssen Biotech (formerly Centocor), Actelion (acquired 2017 for $30B), Janssen-Cilag AG, Janssen Vaccines (formerly Crucell), Tibotec, Intra-Cellular Therapies (acquired 2025), Halda Therapeutics (acquired 2025), OBaris (acquired September 2025)
Key Partnerships:Genmab (monoclonal antibodies, particularly daratumumab), Crucell/Janssen Vaccines (vaccine development), Cellular Biomedicine Group ($245M for CAR-T therapies), University of Pennsylvania School of Nursing (fellowship programs), Microsoft and SONSIEL (NurseHack4Health collaboration), International Council of Nurses (healthcare innovation), NHS Sustainable Development Unit & Sustainable Healthcare Coalition, American Chemical Society Green Chemistry Institute, FUJIFILM (biopharmaceutical manufacturing facility in North Carolina), Pacira (Zilretta expansion partnership, July 2025)
COMPETITION
Position:Leader
Competitors:Eli Lilly & Company (highest market cap in pharma; obesity/diabetes focus), Roche (Swiss pharma; oncology and diagnostics), Pfizer, Merck & Co., AstraZeneca, Novartis, Bristol-Myers Squibb, AbbVie +2 more
LEADERSHIP
Key Executives:
Joaquin Duato - Chairman and Chief Executive Officer
Joseph J. Wolk - Executive Vice President and Chief Financial Officer
Elizabeth Forminard - Executive Vice President, Chief Legal Officer
James Swanson - Executive Vice President and Chief Information Officer
Tim Schmid - Executive Vice President and Worldwide Chairman, MedTech
Vanessa Broadhurst - Executive Vice President, Global Corporate Affairs
Scientific Founders:Robert Wood Johnson (co-founder, 1886), James Wood Johnson (co-founder, 1886), Edward Mead Johnson (founder of J&J baby product division, 1886)
Board Members:Joaquin Duato (Chairman and CEO), Darius Adamczyk (Board Member), Mary C. Beckerle (Board Member), Jennifer A. Doudna (Board Member), Marillyn A. Hewson (Board Member), Paula A. Johnson (Board Member), Hubert Joly (Board Member), Daniel Pinto (Board Member (elected June 2025)), John Morikis (Board Member (elected September 2025))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Johnson & Johnson. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.